SUPAC level 3 changes for MR formulations [Regulatives / Guidelines]

posted by jag009  – NJ, 2019-10-22 23:31 (1814 d 23:19 ago) – Posting: # 20715
Views: 2,982

Hi,

❝ 1. IR product if we change the manufacturing site, do we need to perform BE study as suggested in SUPAC guidance for IR? or it would be okay to justify based on in vitro data?


Did you read the SUPAC guidance for IR?

❝ 2. For MR product SUPAC MR guidance is not clear for any requirement of conducting BE study. where as we do perform Fasting for such changes in manufacturing site change. are we doing correct?


I dont follow. Are you asking if the study should be a fasted study?

J

Complete thread:

UA Flag
Activity
 Admin contact
23,249 posts in 4,885 threads, 1,652 registered users;
64 visitors (0 registered, 64 guests [including 8 identified bots]).
Forum time: 22:50 CEST (Europe/Vienna)

The rise of biometry in this 20th century,
like that of geometry in the 3rd century before Christ,
seems to mark out one of the great ages or critical periods
in the advance of the human understanding.    R.A. Fisher

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5